Profile data is unavailable for this security.
About the company
Aptose Biosciences Inc. is a clinical-stage biotechnology company. The Company is engaged in the development and commercialization of precision medicines addressing unmet clinical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage oral kinase inhibitors under development for hematologic malignancies: tuspetinib (HM43239), an oral, myeloid kinase inhibitor being studied as monotherapy and in combination therapy in the APTIVATE international Phase I/II expansion trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib (CG-806), an oral, dual lymphoid and myeloid kinase inhibitor in Phase I a/b stage development for the treatment of patients with relapsed or refractory hematologic malignancies.
- Revenue in CAD (TTM)0.00
- Net income in CAD-64.20m
- Incorporated2006
- Employees35.00
- LocationAptose Biosciences Inc251 Consumers Rd Suite 1105NORTH YORK M2J 4R3CanadaCAN
- Phone+1 (647) 479-9828
- Fax+1 (416) 798-2200
- Websitehttps://aptose.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Avant Brands Inc | 27.39m | -7.95m | 21.41m | 180.00 | -- | 0.4279 | -- | 0.7818 | -0.0295 | -0.0295 | 0.1043 | 0.1753 | 0.3441 | 0.9712 | 5.02 | 152,172.20 | -9.95 | -15.93 | -12.87 | -19.50 | 39.70 | 37.78 | -28.90 | -63.75 | 0.7269 | -1.25 | 0.262 | -- | 30.75 | 240.26 | 32.78 | -- | -23.24 | -- |
| Numinus Wellness Inc | 23.14m | -26.99m | 22.14m | -- | -- | 2.22 | -- | 0.9569 | -0.1022 | -0.1022 | 0.0877 | 0.0315 | 0.7724 | -- | 11.76 | -- | -90.11 | -77.31 | -106.01 | -84.20 | 33.28 | -- | -116.66 | -323.32 | -- | -14.79 | 0.3876 | -- | 256.95 | -- | 32.59 | -- | -- | -- |
| Rubicon Organics Inc | 40.12m | -1.82m | 22.46m | 180.00 | -- | 0.5931 | 16.95 | 0.5599 | -0.0323 | -0.0323 | 0.7107 | 0.6744 | 0.7228 | 1.23 | 9.92 | 222,869.30 | -3.29 | -18.76 | -4.25 | -24.93 | 63.27 | 55.64 | -4.55 | -42.42 | 0.9322 | 15.08 | 0.2154 | -- | 12.95 | -- | 52.71 | -- | -21.38 | -- |
| Aptose Biosciences Inc | 0.00 | -64.20m | 26.15m | 35.00 | -- | 135.73 | -- | -- | -8.56 | -8.56 | 0.00 | 0.0119 | 0.00 | -- | -- | 0.00 | -180.99 | -63.94 | -342.22 | -71.96 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -22.44 | -- | -38.48 | -- |
| Pharmacielo Ltd | 2.81m | -12.82m | 26.29m | 268.00 | -- | 9.04 | -- | 9.35 | -0.082 | -0.082 | 0.018 | 0.0172 | 0.1046 | 1.27 | 18.23 | -- | -47.70 | -- | -67.05 | -- | -7.08 | -- | -456.04 | -- | 0.1712 | -4.01 | 0.8578 | -- | 172.93 | -- | 45.49 | -- | -- | -- |
| Covalon Technologies Ltd | 25.07m | -4.93m | 27.31m | -- | -- | 1.52 | -- | 1.09 | -0.1994 | -0.1994 | 1.01 | 0.7163 | 0.9589 | 1.84 | 5.96 | -- | -18.86 | -18.06 | -22.78 | -27.10 | 53.90 | 51.89 | -19.67 | -27.06 | 3.25 | -- | 0.0723 | -- | 46.56 | -0.096 | 51.79 | -- | 12.21 | -- |
| Cytophage Technologies Ltd | 0.00 | -4.64m | 27.40m | -- | -- | 11.55 | -- | -- | -0.5489 | -0.5489 | 0.00 | 0.0442 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -165.33 | 0.8283 | -- | -- | -- | -25.88 | -- | -- | -- |
| Devonian Health Group Inc | 5.03m | -4.28m | 29.62m | 6.00 | -- | 2.23 | -- | 5.89 | -0.0304 | -0.0304 | 0.0352 | 0.0897 | 0.2723 | 16.81 | 3.47 | 838,660.00 | -23.17 | -21.02 | -30.01 | -23.96 | 37.90 | 29.96 | -85.08 | -131.97 | 1.11 | -15.22 | 0.0113 | -- | 1.74 | -5.83 | -33.39 | -- | -- | -- |
| Briacell Therapeutics Corp | 0.00 | -17.16m | 29.87m | 5.00 | -- | -- | -- | -- | -1.11 | -1.11 | 0.00 | -0.6875 | 0.00 | -- | -- | -- | -54.70 | -59.37 | -60.36 | -63.11 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 24.35 | -- | -- | -- |
